# Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

> **NCT05904080** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 50 (estimated)

## Conditions studied

- Metastatic Nasopharyngeal Carcinoma
- Recurrent Nasopharyngeal Carcinoma
- Stage IV Nasopharyngeal Carcinoma AJCC v8

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Cabozantinib S-malate
- **PROCEDURE:** Computed Tomography
- **BIOLOGICAL:** Ipilimumab
- **PROCEDURE:** Magnetic Resonance Imaging
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT05904080
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-19
- **Primary completion:** 2028-06-16
- **Final completion:** 2028-06-16
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05904080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05904080, "Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT05904080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*